特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
924080

次世代免疫治療法による先進的癌治療:将来見通し(機会と課題)

Advanced Cancer Therapy with Next-Generation Immunotherapy Approach: Future Prospects (Opportunities and Challenges)

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
次世代免疫治療法による先進的癌治療:将来見通し(機会と課題)
出版日: 2020年03月04日
発行: DelveInsight Business Research LLP
ページ情報: 英文
納期: 即日から翌営業日
担当者のコメント
新型コロナウイルスの感染拡大の影響を考慮して中止になりましたが、2020年3月に都内某所にて、DelveInsight社の免疫療法の専門調査員における同テーマの主催セミナーを開催予定でした。その後も日本における多くの製薬会社様からも引き合いの多かった調査レポートであり、次世代免疫療法の最新トレンド、2035年度までの将来予測をまとめた当レポートは、今後15年後の動向把握のための製薬会社様必見の調査レポートです。15%ディスカウントキャンペーンを継続中ですので、是非お問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

次世代免疫治療は、術後、細胞毒性化学療法、放射線治療、標的治療後の時期癌治療として大きな可能性があります。次世代免疫治療の進歩により、ICOS、OX-40、LAG-3、TIM-3、B7-H3、VISTAなどの標的への関心が生まれています。

当レポートでは、次世代免疫治療法による先進的癌治療について調査し、次世代免疫治療の概要と技術動向、薬剤開発動向、主要7大市場の動向などについてまとめています。

第1章 主なインサイト

第2章 エグゼクティブサマリー

第3章 次世代免疫治療の競争力

第4章 次世代免疫治療の市場競合

第5章 次世代免疫治療における技術革新

第6章 次世代免疫治療における参入企業の多変量解析

第7章 次世代免疫治療市場の概要

  • 2035年の市場シェア分布

第8章 パイプライン治療薬

第9章 概要:次世代免疫治療

第10章 将来見通しと課題

第11章 SWOT分析

第12章 疫学と予測

第13章 新興薬剤

第14章 標的別評価

第15章 病期、標的別評価

第16章 後期製品(第3相)

第17章 中期製品(第2相)

第18章 初期製品(第1相)

第19章 前臨床・創薬段階製品

第20章 B7-H3

第21章 ICOS

第22章 LAG-3

第23章 OX40

第24章 TIM-3

第25章 VISTA

第26章 病期・製品タイプ別評価

第27章 投与ルート別評価

第28章 病期・投与ルート別評価

第29章 分子タイプ別評価

第30章 病期・分子タイプ別評価

第31章 特許分析

第32章 7大市場分析

第33章 7大市場の市場見通し

第34章 市場促進因子

第35章 市場障壁

第36章 付録

第37章 DelveInsightの能力

第38章 免責事項

第39章 DelveInsightについて

図表

List of Tables

  • Table 1: Competitive Intensity of Next Generation Immunotherapies
  • Table 2: Timeline of selected key events in modern cancer immunology, 1868-2017
  • Table 3: Status of selected single-agent Cancer Immunotherapies
  • Table 4: Comparison of Emerging Drugs
  • Table 5: Comparison of Emerging Drugs
  • Table 6: Assessment by Target Type
  • Table 7: Assessment by Stage and Target Type
  • Table 8: Late Stage Products (Phase III) of Next Generation Immunotherapies
  • Table 9: Mid Stage Products (Phase II) of Next Generation Immunotherapies
  • Table 10: Early Stage Products (Phase I) of Next Generation Immunotherapies
  • Table 11: Targeted Indications for B7-H3
  • Table 12: Omburtamab, Clinical Trial Description, 2020
  • Table 13: MGC018, Clinical Trial Description, 2020
  • Table 14: Enoblitizumab, Clinical Trial Description, 2020
  • Table 15: Targeted Indications of ICOS
  • Table 16: GSK3359609, Clinical Trial Description, 2020
  • Table 17: Vopratelimab, Clinical Trial Description, 2020
  • Table 18: KY1044, Clinical Trial Description,2020
  • Table 19: BMS-986226, Clinical Trial Description, 2020
  • Table 20: XmAb23104, Clinical Trial Description,2020
  • Table 21: Targeted Indications of LAG-3
  • Table 22: MGD013, Clinical Trial Description, 2020
  • Table 23: Relatlimab, Clinical Trial Description, 2020
  • Table 24: Eftilagimod Alpha, Clinical Trial Description, 2020
  • Table 25: LAG525, Clinical Trial Description, 2020
  • Table 26: MK-4280, Clinical Trial Description, 2020
  • Table 27: FS118, Clinical Trial Description, 2020
  • Table 28: REGN3767, Clinical Trial Description, 2020
  • Table 29: XmAb22841, Clinical Trial Description, 2020
  • Table 30: INCAGN2385, Clinical Trial Description, 2020
  • Table 31: RO7247669, Clinical Trial Description, 2020
  • Table 32: TSR-033 , Clinical Trial Description, 2020
  • Table 33: IBI110, Clinical Trial Description, 2020
  • Table 34: Targeted Indications of OX40
  • Table 35: Tavolimab, Clinical Trial Description; 2020
  • Table 36: GSK3174998, Clinical Trial Description, 2020
  • Table 37: PF-04518600, Clinical Trial Description; 2020
  • Table 38: BMS-986178, Clinical Trial Description; 2020
  • Table 39: INCAGN01949, Clinical Trial Description, 2020
  • Table 40: mRNA-2416, Clinical Trial Description; 2020
  • Table 41: ATOR-1015, Clinical Trial Description, 2020
  • Table 42: TAK252/ SL-279252, Clinical Trial Description; 2020
  • Table 43: mRNA-2752, Clinical Trial Description; 2020
  • Table 44: MEDI6469, Clinical Trial Description; 2020
  • Table 45: ABBV-368, Clinical Trial Description, 2020
  • Table 46: IBI101, Clinical Trial Description, 2020
  • Table 47: INBRX-106, Clinical Trial Description, 2020
  • Table 48: HS-130, Clinical Trial Description, 2020
  • Table 49: MOXRO916, Clinical Trial Description, 2020
  • Table 50: Targeted Indications of TIM-3
  • Table 51: TSR-022, Clinical Trial Description, 2020
  • Table 52: MBG453, Clinical Trial Description, 2020
  • Table 53: ONO-7807/BMS-986258, Clinical Trial Description, 2020
  • Table 54: BGB-A425, Clinical Trial Description, 2020
  • Table 55: INCAGN2390, Clinical Trial Description, 2020
  • Table 56: Sym023, Clinical Trial Description, 2020
  • Table 57: RO7121661, Clinical Trial Description, 2020
  • Table 58: LY3321367, Clinical Trial Description, 2020
  • Table 59: Sym022, Clinical Trial Description, 2020
  • Table 60: Targeted Indications of VISTA
  • Table 61: CA-170, Clinical Trial Description, 2020
  • Table 62: Assessment by Stage and Product Type
  • Table 63: Assessment by Route of Administration
  • Table 64: Assessment by Stage and Route of Administration
  • Table 65: Assessment by Molecule Type
  • Table 66: Assessment by Stage and Molecule Type
  • Table 67: 7 Major Market Size of Next generation immunotherapies in the 7MM, in USD Million (2022-2035)
  • Table 68: Market Size of B7-H3, USD Million (2022-2035)
  • Table 69: Market size of B7-H3 by indication, in USD Million (2022-2035)
  • Table 70: Market Size of ICOS, USD Million (2022-2035)
  • Table 71: Market size of ICOS by indication, in USD Million (2022-2035)
  • Table 72: Market Size of LAG-3, USD Million (2022-2035)
  • Table 73: Market size of LAG-3 by indication, in USD Million (2022-2035)
  • Table 74: Market Size of OX40, USD Million (2022-2035)
  • Table 75: Market size of OX40 by indication, in USD Million (2022-2035)
  • Table 76: Market Size of TIM-3, USD Million (2022-2035)
  • Table 77: Market size of TIM-3 by indication, in USD Million (2022-2035)

List of Figures

  • Figure 1: Competitive Intensity of Next Generation Immunotherapies
  • Figure 2: OX40-OX40L interaction model
  • Figure 3: Regulatory approvals for Cancer Immunotherapies in the United States since 2010
  • Figure 4: Overview of the factors contributing to varying response rates to immunotherapy and methods to overcome these barriers
  • Figure 5: Assessment by Target Type
  • Figure 6: Assessment by Stage and Target Type
  • Figure 7: Late Stage Products (Phase III) of Next Generation Immunotherapies
  • Figure 8: Mid Stage Products (Phase II) of Next Generation Immunotherapies
  • Figure 9: Early Stage Products (Phase I) of Next Generation Immunotherapies
  • Figure 10: Pre-clinical and Discovery Products of Next Generation Immunotherapies
  • Figure 11: Assessment by Stage and Product Type
  • Figure 12: Assessment by Route of Administration
  • Figure 13: Assessment by Stage and Route of Administration
  • Figure 14: Assessment by Molecule Type
  • Figure 15: Assessment by Stage and Molecule Type
  • Figure 16: 7 Major Market Size of Next generation immunotherapies in the 7MM, in USD Million (2022-2035)
  • Figure 17: Total Market Size of B7-H3, USD Million (2022-2035)
  • Figure 18: Market size of B7-H3 by indication, in USD Million (2022-2035)
  • Figure 19: Total Market Size of ICOS, USD Million (2022-2035)
  • Figure 20: Market size of ICOS by indication, in USD Million (2022-2035)
  • Figure 21: Total Market Size of LAG-3, USD Million (2022-2035)
  • Figure 22: Market size of LAG-3 by indication, in USD Million (2022-2035)
  • Figure 23: Total Market Size of OX40, USD Million (2022-2035)
  • Figure 24: Market size of OX40 by indication, in USD Million (2022-2035)
  • Figure 25: Total Market Size of TIM-3, USD Million (2022-2035)
  • Figure 26: Market size of TIM-3 by indication, in USD Million (2022-2035)
目次

The next generation immunotherapies pose a great potential to be a next in line chosen treatment for cancer after surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The advancements in the Next generation immunotherapies generates interest in several targets such as ICOS, OX-40, LAG-3, TIM-3, B7-H3, VISTA and many more. Inhibitory and stimulatory pathways of different immune checkpoints assists the scientist and researchers to move a step forward.

However, the current scenario holds multi-level challenge for the further progress. One of the major challenge is scantiness in identification of the major biomarkers generating a need for distinct clinical study designs for the evaluation of efficacy. Additionally, other factors such as assessment of the efficacious immunotherapies required to develop successful strategies is another unmet need.

Worthwhile, the emerging trend in Next generation immunotherapies with continuous headway movement along with new emerging technologies for the development of targeted therapies lightens the hopes for better therapeutic alternatives. Concurrently, the increased funding for R&D by big players and organizations have enthused the scientists to put pedal on metal for further innovations.

The lucrative opportunities in the field of discovery is directly translated from the competitive intensity for different targets. Presently, OX-40 wins the innovation race with maximum number of products followed by LAG-3, TIM-3 and ICOS respectively. On the other hand, B7-H3 and VISTA, have lesser number of products in the clinical trials and holds a chance to catch up to the sprint.

With respect to the phase of development, more than twenty are being evaluated for early stage. Nevertheless, quite a lot products are also being developed for pre-clinical and discovery stage. The moral for potential therapies in the future is boosted to witness more than five products in mid-stage of development. The inference for novelty and newfangled research can be derived from the fewer number of products in late stage with one products in phase III and two in phase II/III. The front-runners for late-stage products belongs to ICOS, B7-H3 and LAG-3.

It is also noteworthy to evaluate the potential of different targets in different oncology indications such as non-small Cell Lung Carcinoma, head and neck cancer, multiple myeloma, gastric cancer, hepatocellular carcinoma, colorectal cancer, breast cancer, melanoma and many more. Bearing in mind the prospective of Next generation immunotherapies, several key players such as GlaxoSmithKline, Jounce Therapeutics, Pfizer, AstraZeneca, Bristol-Myers Squibb, Novartis, Merck are sinking their teeth into advance research and development. Furthermore, to strengthen the pipeline, many companies are entering into other indications such as osteosarcoma, renal cell carcinoma, wilms tumor, endometrial carcinoma, cervical cancer and others.

The market size for LAG-3 and ICOS targeted immunotherapies is anticipated to capture the major market share followed by TIM-3 and OX-40. The widespread scope and robust pipeline of Next generation immunotherapies has added enthusiasm and optimism for the impending therapies.

In this report we have captured the commercial potential of all potential next generation immunotherapies coming in oncology space targeting multiple indications in next 10-15 years.

Table of Contents

1. Key Insights

2. Executive Summary

3. Competitive Intensity of Next Generation Immunotherapies

4. Market Competition of Next Generation Immunotherapies

5. Technological innovations in Next Generation Immunotherapies

6. Multivariate analysis of the key players in Next Generation Immunotherapy

7. Next Generation Immunotherapy Market Overview at a Glance

  • 7.1. Market Share (%) Distribution of Next Generation Immunotherapy in 2035

8. Pipeline Therapeutics (Active Products)

9. Overview: Next Generation Immunotherapy

  • 9.1. Immune Checkpoint Inhibitors
  • 9.2. Next-Generation Immunotherapies
  • 9.3. Co-stimulatory targets
    • 9.3.1. OX40
    • 9.3.2. ICOS (Inducible T cell co-stimulator, CD278)
    • 9.3.3. TIM-3
  • 9.4. Inhibitory pathways
    • 9.4.1. LAG-3
    • 9.4.2. B7-H3
    • 9.4.3. VISTA
  • 9.5. Conclusion

10. Future Prospects and Challenges in Next Generation Immunotherapies

  • 10.1. Current Clinical Challenges in Immunotherapies
  • 10.2. Future direction of improving response rates of Immunotherapy

11. SWOT Analysis

12. Epidemiology and Forecasting Assumptions

13. Emerging Drugs

  • 13.1. Key Cross Competition
  • 13.2. Discovery/Preclinical Key-cross Competition

14. Assessment by Target Type

15. Assessment by Stage and Target Types

16. Late Stage Products (Phase III) of Next Generation Immunotherapies

  • 16.1. Comparative Analysis

17. Mid Stage Products (Phase II) of Next Generation Immunotherapies

  • 17.1. Comparative Analysis

18. Early Stage Products (Phase I) of Next Generation Immunotherapies

  • 18.1. Comparative Analysis

19. Pre-clinical and Discovery Products of Next Generation Immunotherapies

  • 19.1. Comparative Analysis

20. B7-H3

  • 20.1. Targeted Indications for B7-H3
  • 20.2. Omburtamab: Y-mAbs Therapeutics
    • 20.2.1. Drug Description
    • 20.2.2. Other Developmental Activities
    • 20.2.3. Clinical Development
    • 20.2.4. Product Profile
  • 20.3. MGC018: MacroGenics
    • 20.3.1. Drug Description
    • 20.3.2. Other Developmental Activities
    • 20.3.3. Clinical Development
    • 20.3.4. Product Profile
  • 20.4. Enoblituzumab (MGA271): MacroGenics
    • 20.4.1. Drug Description
    • 20.4.2. Other Developmental Activities
    • 20.4.3. Clinical Development
    • 20.4.4. Product Profile

21. ICOS

  • 21.1. Target indications of ICOS
  • 21.2. GSK3359609: GlaxoSmithKline
    • 21.2.1. Drug Description
    • 21.2.2. Other Developmental Activities
    • 21.2.3. Clinical Development
    • 21.2.4. Product Profile
  • 21.3. Vopratelimab (JTX-2011): Jounce Therapeutics
    • 21.3.1. Product Description
    • 21.3.2. Other Developmental Activities
    • 21.3.3. Clinical Development
    • 21.3.4. Product Profile
  • 21.4. KY1044: Kymab
    • 21.4.1. Product Description
    • 21.4.2. Other Developmental Activities
    • 21.4.3. Clinical Development
    • 21.4.4. Product Profile
  • 21.5. BMS-986226 (Anti-ICOS): Bristol-Myers Squibb
    • 21.5.1. Drug Description
    • 21.5.2. Clinical Development
    • 21.5.3. Product Profile
  • 21.6. XmAb23104: Xencor
    • 21.6.1. Product Description
    • 21.6.2. Other Developmental Activities
    • 21.6.3. Clinical Development
    • 21.6.4. Product Profile

22. LAG-3

  • 22.1. Targeted indications of LAG-3
  • 22.2. MGD013: MacroGenics/Zai Lab
    • 22.2.1. Product Description
    • 22.2.2. Other Developmental Activities
    • 22.2.3. Clinical Development
    • 22.2.4. Product Profile
  • 22.3. Relatlimab: Bristol-Myers Squibb/Ono Pharmaceuticals
    • 22.3.1. Drug Description
    • 22.3.2. Other developmental activities
    • 22.3.3. Clinical Development
    • 22.3.4. Product Profile
  • 22.4. Eftilagimod Alpha (IMP321): Immutep
    • 22.4.1. Product Description
    • 22.4.2. Other Developmental Activities
    • 22.4.3. Clinical Development
    • 22.4.4. Product Profile
  • 22.5. LAG525: Novartis
    • 22.5.1. Drug Description
    • 22.5.2. Other developmental activities
    • 22.5.3. Clinical Development
    • 22.5.4. Product Profile
  • 22.6. MK-4280: Merck
    • 22.6.1. Drug Description
    • 22.6.2. Clinical Development
    • 22.6.3. Product Profile
  • 22.7. FS118: F-star Therapeutics
    • 22.7.1. Product Description
    • 22.7.2. Other Developmental Activities
    • 22.7.3. Clinical Development
    • 22.7.4. Product Profile
  • 22.8. REGN3767: Regeneron
    • 22.8.1. Product Description
    • 22.8.2. Other Developmental Activities
    • 22.8.3. Clinical Development
    • 22.8.4. Product Profile
  • 22.9. XmAb22841: Xencor
    • 22.9.1. Product Description
    • 22.9.2. Other Developmental Activities
    • 22.9.3. Clinical Development
    • 22.9.4. Product Profile
  • 22.10. INCAGN2385: Incyte Biosciences/Agenus
    • 22.10.1. Product Description
    • 22.10.2. Other Developmental Activities
    • 22.10.3. Clinical Development
    • 22.10.4. Product Profile
  • 22.11. RO7247669: Roche
    • 22.11.1. Product Description
    • 22.11.2. Clinical Development
    • 22.11.3. Product Profile
  • 22.12. TSR-033: GlaxoSmithKline
    • 22.12.1. Drug Description
    • 22.12.2. Other Developmental Activities
    • 22.12.3. Clinical Development
    • 22.12.4. Product Profile
  • 22.13. IBI110: Innovent Biologics (Suzhou) Co. Ltd.
    • 22.13.1. Drug Description
    • 22.13.2. Other Developmental Activities
    • 22.13.3. Clinical Development
    • 22.13.4. Product Profile

23. OX40

  • 23.1. Targeted indications of OX40
  • 23.2. Tavolimab (MEDI0562): MedImmune/AstraZeneca
    • 23.2.1. Product Description
    • 23.2.2. Clinical Development
    • 23.2.3. Product Profile
  • 23.3. GSK3174998: GlaxoSmithKline
    • 23.3.1. Drug Description
    • 23.3.2. Other Developmental Activities
    • 23.3.3. Clinical Development
    • 23.3.4. Product Profile
  • 23.4. PF-04518600 (PF-8600): Pfizer
    • 23.4.1. Product Description
    • 23.4.2. Other Developmental Activities
    • 23.4.3. Clinical Development
    • 23.4.4. Product Profile
  • 23.5. BMS-986178: Bristol-Myers Squibb
    • 23.5.1. Product Description
    • 23.5.2. Other Developmental Activities
    • 23.5.3. Clinical Development
    • 23.5.4. Product Profile
  • 23.6. INCAGN1949: Incyte Biosciences/Agenus
    • 23.6.1. Product Description
    • 23.6.2. Other Developmental Activities
    • 23.6.3. Clinical Development
    • 23.6.4. Product Profile
  • 23.7. mRNA-2416: ModernaTX
    • 23.7.1. Product Description
    • 23.7.2. Other Developmental Activities
    • 23.7.3. Clinical Development
    • 23.7.4. Product Profile
  • 23.8. ATOR-1015/ADC-1015: Alligator Bioscience
    • 23.8.1. Product Description
    • 23.8.2. Other Developmental Activities
    • 23.8.3. Clinical Development
    • 23.8.4. Product Profile
  • 23.9. TAK252/ SL-279252: Shattuck Labs/Takeda
    • 23.9.1. Product Description
    • 23.9.2. Other Developmental Activities
    • 23.9.3. Clinical Development
    • 23.9.4. Product Profile
  • 23.10. mRNA-2752: ModernaTX
    • 23.10.1. Product Description
    • 23.10.2. Other Developmental Activities
    • 23.10.3. Clinical Development
    • 23.10.4. Product Profile
  • 23.11. MEDI6469: MedImmune/AstraZeneca
    • 23.11.1. Product Description
    • 23.11.2. Other Developmental Activities
    • 23.11.3. Clinical Development
    • 23.11.4. Product Profile
  • 23.12. ABBV-368: AbbVie
    • 23.12.1. Drug Description
    • 23.12.2. Other Developmental Activities
    • 23.12.3. Clinical Development
    • 23.12.4. Product Profile
  • 23.13. IBI101 (Anti-OX40 Monoclonal Antibody): Innovent Biologics
    • 23.13.1. Drug Description
    • 23.13.2. Other Developmental Activities
    • 23.13.3. Clinical Development
    • 23.13.4. Product Profile
  • 23.14. INBRX-106: Inhibrx
    • 23.14.1. Drug Description
    • 23.14.2. Other Developmental Activities
    • 23.14.3. Clinical Development
    • 23.14.4. Product Profile
  • 23.15. HS-130: Heat biologics
    • 23.15.1. Drug Description
    • 23.15.2. Other Developmental Activities
    • 23.15.3. Clinical Development
    • 23.15.4. Product Profile
  • 23.16. MOXR0916/RG7888: Genentech
    • 23.16.1. Drug Description
    • 23.16.2. Clinical Development
    • 23.16.3. Product Profile

24. TIM-3

  • 24.1. Targeted Indications of TIM-3
  • 24.2. TSR-022: GlaxoSmithKline
    • 24.2.1. Drug Description
    • 24.2.2. Other Developmental Activities
    • 24.2.3. Clinical Development
    • 24.2.4. Product Profile
  • 24.3. MBG453: Novartis
    • 24.3.1. Product Description
    • 24.3.2. Clinical Development
    • 24.3.3. Product Profile
  • 24.4. ONO-7807/BMS-986258: Bristol-Myers Squibb/ Ono Pharmaceuticals
    • 24.4.1. Drug Description
    • 24.4.2. Other Developmental Activities
    • 24.4.3. Clinical Development
    • 24.4.4. Product Profile
  • 24.5. BGB-A425 +/- Tislelizumab: BeiGene
    • 24.5.1. Product Description
    • 24.5.2. Clinical Development
    • 24.5.3. Product Profile
  • 24.6. INCAGN2390: Incyte Biosciences/Agenus
    • 24.6.1. Product Description
    • 24.6.2. Other Developmental Activities
    • 24.6.3. Clinical Development
    • 24.6.4. Product Profile
  • 24.7. Sym023: Symphogen
    • 24.7.1. Product Description
    • 24.7.2. Other Developmental Activities
    • 24.7.3. Clinical Development
    • 24.7.4. Product Profile
  • 24.8. RG7769/RO7121661: Roche
    • 24.8.1. Product Description
    • 24.8.2. Clinical Development
    • 24.8.3. Product Profile
  • 24.9. LY3321367: Eli Lilly
    • 24.9.1. Product Description
    • 24.9.2. Clinical Development
    • 24.9.3. Product Profile
  • 24.10. Sym022: Symphogen
    • 24.10.1. Product Description
    • 24.10.2. Other Developmental Activities
    • 24.10.3. Clinical Development
    • 24.10.4. Product Profile

25. VISTA

  • 25.1. Targeted indications of VISTA
  • 25.2. CA-170: Curis/Aurigene
    • 25.2.1. Drug Description
    • 25.2.2. Other Developmental Activities
    • 25.2.3. Clinical Development
    • 25.2.4. Product Profile

26. Assessment by Stage and Product Type

27. Assessment by Route of Administration

28. Assessment by Stage and Route of Administration

29. Assessment by Molecule Type

30. Assessment by Stage and Molecule Type

31. Patent analysis of Next Generation Immunotherapies

32. Next Generation Immunotherapies: 7 Major Market Analysis

  • 32.1. Key Findings

33. Market Outlook in the 7MM

  • 33.1. Market Size of Next generation immunotherapies in the 7MM Countries
  • 33.2. B7-H3
    • 33.2.1. Total Market size of B7-H3
    • 33.2.2. Market Size of B7-H3 by indication
  • 33.3. ICOS
    • 33.3.1. Total Market size of ICOS
    • 33.3.2. Market Size of ICOS by indication
  • 33.4. LAG-3
    • 33.4.1. Total Market size of LAG-3
    • 33.4.2. Market Size of LAG-3 by indication
  • 33.5. OX40
    • 33.5.1. Total Market size of OX40
    • 33.5.2. Market Size of OX40 by indication
  • 33.6. TIM-3
    • 33.6.1. Total Market size of TIM-3
    • 33.6.2. Market Size of TIM-3 by indication

34. Market Drivers

35. Market Barriers

36. Appendix

  • 36.1. Report Methodology

37. DelveInsight Capabilities

38. Disclaimer

39. About DelveInsight

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.